Yahoo Finance

(Bloomberg) -- Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. filed to list its shares in Hong Kong, adding to the growing number of publicly traded mainland Chinese firms looking to have their stock trade in the financial hub.

Most Read from Bloomberg

• NYC’s Subway Violence Deters Drive to Bring Workers Back to Office

• Can American Drivers Learn to Love Roundabouts?

• Don’t Shrink the Bus

• Is This Weird Dome the Future of Watching Sports?

• Dutch Central Bank Restores Amsterdam’s ‘Ugliest Building’

Chinese companies whose shares already trade in the mainland are betting that adding a Hong Kong listing would make it easier for foreign funds to invest in them. Hengrui’s share sale could fetch at least $2 billion, people familiar with the situation have said.

Morgan Stanley, Citigroup Inc. and Huatai Securities Co. are arranging the deal.

Most Read from Bloomberg Businessweek

• The US’s Worst Fears of Chinese Hacking Are on Display in Guam

• Elon Musk Is Not Having a Happy New Year

• Luxury Brands Need to Get Over Their Youth Fixation to Offset Drag From Trump’s Tariffs

• Why Everyone’s Obsessed With Meat Sticks and Cottage Cheese

• Zyn’s Online Hype Risks Leading to the Nicotine Pouches’ Downfall

©2025 Bloomberg L.P.